2020
220-LB: Glucagon Promotes Hepatic Autophagy by AMPK-Mediated mTORC1 Inhibition
GALSGAARD K, WEWER ALBRECHTSEN N, HOLST J, SHULMAN G, PETERSEN K, NASIRI A, CLINE G, ZHANG X, LEE J, HUBBARD B. 220-LB: Glucagon Promotes Hepatic Autophagy by AMPK-Mediated mTORC1 Inhibition. Diabetes 2020, 69 DOI: 10.2337/db20-220-lb.Peer-Reviewed Original ResearchSpouse/partnerDohme Corp.Hepatic autophagyMerck SharpKidney diseaseNovo Nordisk A/SAMP kinaseGlucagon treatmentPlasma glucagon concentrationsAdvisory PanelKrebs-Henseleit bicarbonate bufferHepatic protein metabolismNational InstituteNovo Nordisk FoundationMarkers of autophagyHepatic glucose metabolismFasted male ratsProtein/amino acid metabolismGlucagon's roleGlucagon concentrationsGlucagon infusionMale ratsAwake miceNovo Nordisk A/S.Glucose metabolism
2001
Prevention of fat-induced insulin resistance by salicylate
Kim J, Kim Y, Fillmore J, Chen Y, Moore I, Lee J, Yuan M, Li Z, Karin M, Perret P, Shoelson S, Shulman G. Prevention of fat-induced insulin resistance by salicylate. Journal Of Clinical Investigation 2001, 108: 437-446. PMID: 11489937, PMCID: PMC209353, DOI: 10.1172/jci11559.Peer-Reviewed Original ResearchConceptsType 2 diabetesLipid infusionInsulin resistanceGlucose uptakeInsulin actionWhole-body glucose uptakeFat-induced insulin resistanceSkeletal muscleHigh-dose salicylatesHyperinsulinemic-euglycemic clampWild-type miceInsulin-stimulated glucose uptakeSkeletal muscle insulinIRS-1-associated PISerine kinase cascadeLipid-induced effectsAwake ratsAwake miceKnockout miceMuscle insulinInfusionTherapeutic agentsSalicylate actionKinase cascadeIKK beta